CHICAGO– Cardiosense, a digital health company developing AI-enabled solutions for cardiac disease management, announced the appointment of Eric Meizlish as Chief Executive Officer. Meizlish succeeds co-founder Amit Gupta, who will remain with the company as Chief Strategy Officer.
The leadership change comes as Cardiosense builds on recent milestones, including FDA clearance of its CardioTag sensor, peer-reviewed results from the SEISMIC-HF I study, and continued enrollment in the pivotal SEISMIC-HF II trial. Earlier this year, the company also expanded its executive team with the addition of John Martin, M.D., as Executive Vice President and Chief Medical Officer.
“Since co-founding the company, Amit has worked tirelessly to set the strategic vision and mission for Cardiosense, while achieving significant product and regulatory milestones, assembling a world-class team, and establishing a strong culture and foundation for continued growth,” said Jeff Trost, Managing Partner of the Laerdal Million Lives Fund. “We want to thank Amit for his leadership, and we are excited to continue working together in his new role alongside Eric.”
Daniel Gottlieb, Director at Broadview Ventures, said, “Eric’s appointment marks an important step in Cardiosense’s evolution as we scale our platform to democratize precision cardiac care. By delivering actionable insights without costly implantable sensors, the company is well-positioned to expand its impact, and Eric is the right leader to accelerate this momentum.”
Meizlish brings extensive experience in healthcare technology and growth-stage companies. He co-founded and served as president of Lumere, a clinical evidence and analytics company acquired by Global Healthcare Exchange, where he later became Senior Vice President of Strategy and Corporate Development. Most recently, he was CEO of Prendio-BioProcure, a cloud-based eProcurement platform for the life sciences industry.
“With the talent and innovation already in place at Cardiosense, we can transform how cardiac disease is managed,” Meizlish said. “Our team has created a technical capability that has never existed before: the ability to accurately predict volumes and pressures within the heart, non-invasively. Our next chapter is about scaling a platform that delivers these key measures to patients and providers to improve care and change the trajectory of heart disease.”
Gupta, reflecting on the transition, added: “We started Cardiosense with the goal of changing how cardiac disease is managed by building a platform for broadly accessible, precision cardiac care. The accomplishments to date provide a strong foundation and I look forward to working with Eric, whose leadership and proven track record scaling healthtech companies make him the right person to lead us going forward.”
